Rana R. McKay

University of California, San Diego
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (73)

Sensitivity analysis: non-MSI-H comparison. (A) Standardized mean difference is shown for features pre- and post- adjustment for the TMB10+ cohort. Propensity-adjusted comparison of ICI (tTMB≥10) vs. taxanes (any tTMB level) is shown for (B) TTNT and (C) OS among the cohort excluding MSI-H.

Year:

2026

Purpose: Immune checkpoint inhibitors (ICI) have shown limited efficacy in unselected patients with metastatic castration-resistant prostate cancer (mCRPC). However, ICIs are approved for biomarker-defined subsets: microsatellite instability–high (MSI-H) and/or high tumor mutational burden (TMB-H). The efficacy of ICIs in TMB-H but not MSI-H disease remains unclear, and limited data exist evaluating ICI outcomes associated with blood-based MSI (bMSI) in mCRPC. Experimental Design: This study used the United States–based deidentified Flatiron Health–Foundation Medicine prostate cancer Clinico-Genomic Database. Patients with tissue-assessed MSI (tMSI) and TMB (tTMB) status by an algorithm supporting an FDA-approved CDx for pembrolizumab were included if treated with single-agent ICI. Separately, outcomes on ICI associated with bMSI were assessed, including if treated with single-agent ICI or taxane. Results: Among 2,965 patients with mCRPC, tMSI-H (3.2%) was nearly always also tTMB ≥10 mut/Mb (4.7%). In 84 ICI-treated patients, time to next treatment (TTNT) and overall survival (OS) were more favorable in tMSI-H with any TMB [TTNT HR, 0.18; 95% confidence interval (CI), 0.09–0.37 and OS HR, 0.32; 95% CI, 0.15–0.66] and tTMB ≥10 without tMSI-H (TTNT HR, 0.18; 95% CI, 0.04–0.48 and OS HR, 0.20; 95% CI, 0.05–0.77) compared with tTMB Conclusions: These findings add support for tTMB and tMSI in predicting ICI monotherapy benefit in mCRPC and provide evidence supporting bMSI testing when tissue is unavailable.

Year:

2026

Introduction We evaluated the incidence of anxiety, depression, and suicidality amongst TC survivors and the impact of chemotherapy on these outcomes. Methods We conducted a retrospective cohort study of men diagnosed with TC in the United States Veterans Affairs Health System from 1990 to 2016. De novo anxiety or depression was a composite endpoint comprised of diagnosis codes for anxiety, depression, or medications used to treat these diagnoses. Incident suicidality was defined as a diagnosis code for suicidal ideation. 2022 TC patients were compared in a 1:3 ratio to 6375 controls. Cox proportional hazards models were employed for statistical analysis. Results Mean age at diagnosis was 42.6 years. 5‐year cumulative incidence of anxiety or depression was 53.4% in TC patients and 35% for controls ( p < 0.001). TC patients were more likely to develop anxiety or depression (HR 1.66, 95% CI 1.56–1.78, p < 0.001) and suicidality (HR 22.99, 95% CI 17.52–30.17, p < 0.001). In the TC cohort, factors associated with a higher risk of anxiety or depression were divorce (HR 1.15, 95% CI 1.00–1.32, p = 0.044), unemployment (HR 1.68, 95% CI 1.47–1.9, p < 0.001), and receipt of chemotherapy (HR 1.20, 95% CI 1.06–1.35, p < 0.001). Conclusions Psychological morbidity due to depression, anxiety, and suicidality is high among TC survivors. In our analysis chemotherapy increases the rates of psychosocial morbidity. Clinicians should be proactive in screening and intervening for these diagnoses in TC survivors to provide early intervention and improve health comes.

Year:

2026

Background The expansion of treatment options for prostate cancer (PC) has improved disease‐specific and overall survival outcomes but has also raised questions about the optimal level of treatment needed for patients based on their individual prognosis and accounting for potential toxicity, incorporating quality of life considerations. Methods A panel of experts met to discuss current controversies in the care of patients with PC across the disease continuum. Multidisciplinary experts review advances and persistent uncertainties in biomarker‐guided assessment, imaging, and systemic therapy for prostate cancer. The discussion outlines priority gaps in evidence that must be addressed to optimize individualized patient care. Results Workshop topics included use of genomic biomarkers and artificial intelligence‐guided tools to identify and manage high‐risk and very‐high risk localized disease, management of biochemical recurrence, identification of patients with metastatic hormone‐sensitive PC who warrant treatment escalation, radiopharmaceutical therapy for metastatic castration‐resistant PC including optimal sequencing of approved therapies, role of imaging in identification and management of extraprostatic disease, and lifestyle interventions to optimize survivorship. Conclusions Many questions remain about management of PC related to biomarker‐based risk stratification to guide treatment selection, use of prostate‐specific membrane antigen‐positron emission tomography, and balancing the risk for PC‐related death with risks for treatment‐related toxicity. Ongoing research efforts are needed to optimize risk‐based treatment, sequence of therapies throughout the disease continuum, and survivorship care.

Year:

2026

PURPOSE Increased heterogeneity in outcomes has been observed postnephrectomy in patients with renal cell carcinoma (RCC), with standard clinical parameters being primarily used for risk assessment. Currently, no blood-based biomarkers are available for molecular residual disease (MRD) detection in RCC. Herein, we performed a multicenter, real-world evaluation of the prognostic value of circulating tumor DNA (ctDNA) in resected RCC. METHODS This real-world evidence-based multi-institutional study included a cohort of 77 patients with stage I-IV RCC. Longitudinal ctDNA testing was performed on plasma samples (n = 295) using a clinically validated, personalized, tumor-informed ctDNA assay (Signatera, Natera, Inc, Austin, TX). ctDNA results were analyzed, and association with recurrence-free survival was assessed. RESULTS The patient cohort included 77 patients with stage I-IV RCC (clear cell: 64, non–clear cell: 13). Patients who tested ctDNA-positive during the MRD window experienced worse prognosis and a higher likelihood of recurrence (hazard ratios, 18; P < .0001) compared with their ctDNA-negative counterparts. CONCLUSION Overall, we demonstrate the utility of ctDNA testing for MRD detection. Future prospective studies in RCC would be needed to validate the utility of ctDNA in informing clinical decision making.

Year:

2026

Introduction The 12th Annual 2025 Coffey—Holden Prostate Cancer Academy (CHPCA) Meeting, “Deciphering Resistance: Beyond the Androgen Paradigm,” was held at the University of California, Los Angeles (UCLA), Luskin Conference Center, in Los Angeles, CA, from June 19 to 22, 2025. Methods The CHPCA Meeting is a discussion‐focused conference held annually by the Prostate Cancer Foundation (PCF), for in‐depth academic analysis of emerging research with the greatest potential to drive new understandings and treatments for prostate cancer. The 2025 CHPCA Meeting included attendance by 79 academic investigators and 39 talks over 8 sessions. Results The session topics included: drug discovery in academia, non‐apoptotic cell death mechanisms, understanding and overcoming treatment resistance, chromosomal instability (CIN) as a driver of metastasis and treatment resistance, targeting metastatic sites, immunotherapy sensitizers, and optimizing therapy delivery and biomedical engineering. Discussion This meeting report summarizes the presentations from the 2025 CHPCA Meeting. We hope that disseminating this information will directly contribute to novel research efforts and improved treatment strategies for patients with prostate cancer.

Year:

2025

Comparison of the frequencies of additional molecular features between non-castrate (NC) and castrate (C) samples in ATMm, BRCA2m, HRDother, and HRP groups. The significant differences between the two groups are highlighted (red box).

Year:

2025

Purpose: Homologous recombination/DNA damage repair (HRR) alterations (HRRalt) are found in around 30% of patients with advanced prostate cancer and have been associated with worse prognosis in the metastatic castrate-resistant setting. However, there are limited data with regard to their association with outcomes of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Experimental Design: This study used a de-identified nationwide (U.S.-based) prostate cancer clinico-genomic database. Patients with de novo mHSPC treated with androgen deprivation therapy intensification with either an androgen receptor pathway inhibitor (ARPI) or a taxane who underwent tissue biopsy within 90 days of mHSPC diagnosis were included. Time to castrate resistance (TTCR) and overall survival (OS) were compared between patients with non-altered HRR and those with HRRalt in any of 14 prespecified genes per the olaparib monotherapy FDA label. TTCR and OS indexed from mHSPC diagnosis were evaluated with Cox proportional hazard models adjusted for baseline prognostic factors. Results: Of 637 eligible patients included in our analysis, 181 harbored HRRalt (28.4%). Compared with patients with non-altered HRR, those with HRRalt had less favorable TTCR when treated with an ARPI [adjusted HR (aHR) = 1.58; 95% confidence interval (CI), 1.17–2.14] or a taxane (aHR = 1.77; 95% CI, 1.3–2.4). Additionally, OS was directionally less favorable in patients with HRRalt (ARPI: aHR = 1.12; 95% CI, 0.80–1.57 and taxane: aHR = 1.23; 95% CI, 0.88–1.72). Conclusions: To date, this is the largest real-world natural history study evaluating the association of HRRalt with outcomes in the mHSPC setting. These data may inform future clinical trial design and counseling of these patients. See related commentary by Graham and Yu, p. 4001

Year:

2025

Outcomes on ARPI or taxane by CDK12alt status. Outcomes for CDK12alt vs. no CDK12alt are shown on ADT + ARPI for (A) TTCRPC and (C) OS. Outcomes for CDK12alt vs. no CDK12alt are shown on ADT + taxane for (B) TTCR and (D) OS. Abbreviations: aHR, adjusted hazard ratio; alt, alteration; ARPI, androgen receptor pathway inhibitor; CI, confidence interval; CRPC, castrate-resistant prostate cancer; doce, docetaxel; TTCR, time to castrate-resistance; OS, overall survival.

Year:

2025

Outcomes on ARPI or taxane by ATMalt status. Outcomes for ATMalt vs. no ATMalt are shown on ADT + ARPI for (A) TTCR and (C) OS. Outcomes for ATMalt vs. no ATMalt are shown on ADT + taxane for (B) TTCR and (D) OS. Abbreviations: aHR, adjusted hazard ratio; alt, alteration; ARPI, androgen receptor pathway inhibitor; CI, confidence interval; CRPC, castrate-resistant prostate cancer; doce, docetaxel; TTCR, time to castrate-resistance; OS, overall survival.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (81)

Aditya Bagrodia

University of Texas Southwestern

UNITED STATES
View details

Andrew Armstrong

Professor

Duke Cancer Institute

UNITED STATES
View details

William Huang

Professor (Clinical)

New York University Grossman School of Medicine

UNITED STATES
View details

Ulka Vaishampayan

Professor

University of Michigan

UNITED STATES
View details

David Braun

Assistant Professor, Principal Investigator

Yale University Yale Cancer Center

UNITED STATES
View details

Oliver Sartor

Tulane University School of Medicine

UNITED STATES
View details

Pedro Barata

Associate Professor of Medicine

University Hospitals Seidman Cancer Center

UNITED STATES
View details

John Lozada

University of Rochester Medical Center

UNITED STATES
View details

Benedito A. Carneiro

-

UNITED STATES
View details

George Sledge

-

UNITED STATES
View details

Grace Blitzer

University of Wisconsin-Madison

UNITED STATES
View details

Bose Kochupurakkal

Senior Scientist

Dana-Farber Cancer Institute

UNITED STATES
View details

Phillip Palmbos

Assistant Professor

University of Michigan Hospital

UNITED STATES
View details

Tian Zhang

University of Texas Southwestern

UNITED STATES
View details

Amirali Salmasi

Associate Professor

UC San Diego Health System

UNITED STATES
View details

Joshua Lang

Professor

University of Wisconsin-Madison

UNITED STATES
View details

Natalie Reizine

Assistant Professor

University of Chicago

UNITED STATES
View details

Arul M Chinnaiyan

University of Michigan

UNITED STATES
View details

Eliezer Van Allen

Professor

Harvard University

UNITED STATES
View details

Scott Tagawa

Weill Cornell Medicine

UNITED STATES
View details

Emil Lou

University of Minnesota

UNITED STATES
View details

Biren Saraiya

Assistant Professor of Medicine

Rutgers Cancer Institute of New Jersey

UNITED STATES
View details

Ari VanderWalde

Global Head of Clinical Trials

-

UNITED STATES
View details

Young Whang

University of North Carolina at Chapel Hill School of Medicine

UNITED STATES
View details

Rahul Parikh

Associate Professor of Medicine

University of Kansas Medical Center

UNITED STATES
View details

Eugene Shenderov

Associate Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Kent Mouw

Assistant Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

HAMID EMAMEKHOO

University of Wisconsin-Madison

UNITED STATES
View details

Justin E. Wilson

Associate Professor

-

UNITED STATES
View details

Alicia Morgans

Dana-Farber Cancer Institute

UNITED STATES
View details

Justin Hwang

Associate Professor

University of Minnesota

UNITED STATES
View details

Shuang G. Zhao

University of Wisconsin-Madison

UNITED STATES
View details

Chadi Hage Chehade

Huntsman Cancer Institute

UNITED STATES
View details

Toni Choueiri

Director, Lank Center for Genitourinary Oncology

Dana-Farber Cancer Institute

UNITED STATES
View details

Wenxin Xu

Assistant Professor of Medicine

Dana-Farber Cancer Institute

UNITED STATES
View details

Jinhua Wang

professor

University of Minnesota System

UNITED STATES
View details

Umang Swami

University of Utah

UNITED STATES
View details

Rohan Garje

Clinical Associate professor

Iowa State University

UNITED STATES
View details

Daniel J. George

Professor

Duke University

UNITED STATES
View details

Elisabeth I. Heath

Wayne State University School of Medicine

UNITED STATES
View details

Stacy Loeb

Professor

NYU School of Medicine

UNITED STATES
View details

Azhar Khandekar

National Cancer Institute

UNITED STATES
View details

Zeynep Irem Ozay

University of Utah Health Huntsman Cancer Institute

UNITED STATES
View details

Alan Haruo Bryce

Chief Clinical Officer

City of Hope

UNITED STATES
View details

David Kosoff

University of Wisconsin-Madison

UNITED STATES
View details

Noel Warfel

Associate Professor

Medical University of South Carolina

UNITED STATES
View details

Josep Domingo-Domenech

Professor

Mayo Clinic

UNITED STATES
View details

Heather H. Cheng

Professor

University of Washington

UNITED STATES
View details

Menggang Yu

Professor

University of Michigan

UNITED STATES
View details

Jacob Orme

Assistant Professor

Mayo Clinic

UNITED STATES
View details

Ludmil Alexandrov

Professor

University of California, San Diego

UNITED STATES
View details

Scott M Dehm

Faculty, Professor

University of Minnesota

UNITED STATES
View details

Marina N Sharifi

Assistant Professor

University of Wisconsin-Madison

UNITED STATES
View details

Neal Lindeman

Vice Chair, Molecular Pathology and Laboratory Medicine

Weill Cornell Medicine

UNITED STATES
View details

Anne Cress

Professor

University of Arizona

UNITED STATES
View details

Nischalan Pillay

Professor

University College London

UNITED KINGDOM
View details

Emmanuel S. Antonarakis

-

UNITED STATES
View details

Carly Miller

University of Minnesota

UNITED STATES
View details

Jonathan Chou

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Jeffrey S Miller

University of Minnesota System

UNITED STATES
View details

Felix Y. Feng

University of California

UNITED STATES
View details

Atish Choudhury

Dana-Farber Cancer Institute

UNITED STATES
View details

Minetta Liu

Research Collaborator, Professor

Mayo Clinic

UNITED STATES
View details

Shailender Singh Chauhan

Staff Scientist II

Medical University of South Carolina

UNITED STATES
View details

Charles Nguyen

Assistant Clinical Professor

City Of Hope National Medical Center

UNITED STATES
View details

Megan E.V. Caram

University of Michigan

UNITED STATES
View details

Peter S. Nelson

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Adam Olson

Assistant Professor

UPMC Hillman Cancer Center

UNITED STATES
View details

Brent Rose

Associate Professor

UC San Diego Health System

UNITED STATES
View details

S. Percy Ivy

Associate Chief

National Cancer Institute

UNITED STATES
View details

Russell K. Pachynski

Washington University School of Medicine

UNITED STATES
View details

Nicholas Zorko

Assistant Professor

University of Minnesota

UNITED STATES
View details

Neeraj Agarwal

Faculty Member

Dana-Farber Cancer Institute

UNITED STATES
View details

Bradley McGregor

Dana-Farber Cancer Institute

UNITED STATES
View details

Travis Wheeler

Professor

University of Arizona

UNITED STATES
View details

Tanya Dorff

Associate Professor

City Of Hope National Medical Center

UNITED STATES
View details

Dave Hoon

Principal Investigator

The Lundquist Institute

UNITED STATES
View details

Xiaolei Shi

Assistant professor

University of Maryland Medical Center

UNITED STATES
View details

David McDermott

Beth Israel Deaconess Medical Center

UNITED STATES
View details

Veerabhadran Baladandayuthapani

Jeremy M.G. Taylor Collegiate Professor of Biostatistics and Chair of Department of Biostatistics

University of Michigan

UNITED STATES
View details

Mamta Parikh

Associate Professor

University of California Davis Comprehensive Cancer Center

UNITED STATES
View details